Great Day for Biotech Tools:Earnings Up ILMN,LIFE and PacBio (PACB) IPO

Timing is everything and can i buy metronidazole or tinidazole over the counter Pacific Biosciences(PACB) took advantage of a good year for biotech stocks, better earnings for tools and Dx companies and a rebounding IPO market. Pacific Biosciences raised $200M($16) at the midpoint of the expected range and shares advanced to $16.25  with midday volume of over 4M shares. JPMorgan and Morgan Stanley led the offering.The Company does not have significant commercial revenues relying primarily upon government grants. PacBio has developed a third generation, single molecule sequencing platform called SMRT that enables real time analysis of biomolecules with single molecule resolution.As featured in our August 11 posting, many analysts see long term growth in biotech tools such as sequencing, and molecular diagnostic tests as the molecular basis for disease is better understood.

Positive earnings for http://versatilegrannyflats.com.au/versatilegrannyflatskitchendesign3/ Life Technologies (LIFE) $50.75 up 6% and http://shellystearooms.com/shellys-tea-rooms-news-winter-2013/ Illumina (ILMN) $55.30 up 7% drove these stocks higher with better than expected results.Illumina had Q3 revenue of $237.3M a 50% increase over the same period last year with non-GAAP income of $40.7M or $0.30/share. Cash flow was $54.8M with a net cash position on the balance sheet of $806.8M.LIFE announced Q3 Revenues of $869M an 8% increase over the same period last year with Non-GAAP earnings of $165M or $0.87/share. Cash flow was $215 M with net cash on the balance sheet at $537M. Earlier last quarter LIFE purchased emerging tools and sequencing player Ion Torrent for $375M with cash and stock.

Another tools and biotech equipment player Thermo-Scientific (TMO) $51.27 traded up 1.8% beating EPS estimates $0.90 vs Wall Street $0.83 on $2.68B in sales. Beckman-Coulter reports tonite.

Raygent » Successful IPO’s in Genomics Could Ignite Biotech Stocks

No comments yet.

Leave a Reply